Evidence map›Paper›PMID 39896373›Full record

ArticlePeerJ. Computer science2024

Enhanced diagnosing patients suspected of sarcoidosis using a hybrid support vector regression model with bald eagle and chimp optimizers.

Guogang Xie, Hani Attar, Ayat Alrosan, Sally Mohammed Farghaly Abdelaliem, Amany Anwar Saeed Alabdullah, Mohanad Deif

Abstract read
In one paragraph

Article in PeerJ. Computer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guogang Xie *Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Hani AttarDepartment of Electrical Engineering, Zarqa University, Zarqa, Jordan.
Ayat AlrosanSchool of Computing, Skyline University, Sharjah, United Arab Emirates.
Sally Mohammed Farghaly AbdelaliemDepartment of Nursing Management and Education, Princess Nourah bint Abdulrahman, Riyadh, Saudi Arabia.
Amany Anwar Saeed AlabdullahDepartment of Maternity and Pediatric Nursing, College of Nursing, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Mohanad Deif *Department of Artificial Intelligence, College of Information Technology, Misr University for Science & Technology, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Searching for a reliable indicator of treatment response in sarcoidosis remains a challenge. The use of the soluble interleukin 2 receptor (sIL-2R) as a measure of disease activity has been proposed by researchers. A machine learning model was aimed to be developed in this study to predict sIL-2R levels based on a patient's serum angiotensin-converting enzyme (ACE) levels, potentially aiding in lung function evaluation. A novel forecasting model (SVR-BE-CO) for sIL-2R prediction is introduced, which combines support vector regression (SVR) with a hybrid optimization model (BES-CO); The hybrid optimization model composed of Bald Eagle Optimizer (BES) and Chimp Optimizer (CO) model. In this forecasting model, the hyper-parameters of the SVR model are optimized by the BES-CO hybrid optimization model, ultimately improving the accuracy of the predicted sIL-2R values. The hybrid forecasting model SVR-BE-CO model was evaluated against various forecasting methods, including Hybrid SVR with Firefly Algorithm (SVR-FFA), decision tree (DT), SVR with Gray Wolf Optimization (SVR-GWO) and random forest (RF). It was demonstrated that the hybrid SVR-BE-CO model surpasses all other methods in terms of accuracy.

Indexed as

Angiotensin converting enzymeBald eagle searchChimp OptimizerMachine learingSarcoidosisSoluble IL-2 receptor

Identifiers

PMID39896373
PMCPMC11784889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.